Stakeholder assessment of the evidence for cancer genomic tests: Insights from three case studies

Patricia A. Deverka, Sheri D. Schully, Naoko Ishibe, Josh J. Carlson, Andrew Freedman, Katrina A.B. Goddard, Muin J. Khoury, Scott D. Ramsey

Research output: Contribution to journalArticle

Abstract

Purpose: Insufficient evidence on the net benefits and harms of genomic tests in real-world settings is a translational barrier for genomic medicine. Understanding stakeholders assessment of the current evidence base for clinical practice and coverage decisions should be a critical step in influencing research, policy, and practice. Methods: Twenty-two stakeholders participated in a workshop exploring the evidence of genomic tests for clinical and coverage decision making. Stakeholders completed a survey prior to and during the meeting. They also discussed if they would recommend for or against current clinical use of each test. Results: At baseline, the level of confidence in the clinical validity and clinical utility of each test varied, although the group expressed greater confidence for epidermal growth factor receptor mutation and Lynch syndrome testing than for Oncotype DX. Following the discussion, survey results reflected even less confidence for Oncotype DX and epidermal growth factor receptor mutation testing, but not for Lynch syndrome testing. The majority of stakeholders would consider clinical use for all three tests, but under the conditions of additional research or a shared clinical decision-making approach. Conclusion: Stakeholder engagement in unbiased settings is necessary to understand various perspectives about evidentiary thresholds in genomic medicine. Participants recommended the use of various methods for evidence generation and synthesis.

Original languageEnglish (US)
Pages (from-to)656-662
Number of pages7
JournalGenetics in Medicine
Volume14
Issue number7
DOIs
StatePublished - Jul 2012

Keywords

  • EGFR testing
  • Lynch syndrome
  • Oncotype DX
  • evidence-based decision making
  • genomic testing
  • stakeholder engagement

ASJC Scopus subject areas

  • Genetics(clinical)

Fingerprint Dive into the research topics of 'Stakeholder assessment of the evidence for cancer genomic tests: Insights from three case studies'. Together they form a unique fingerprint.

  • Cite this

    Deverka, P. A., Schully, S. D., Ishibe, N., Carlson, J. J., Freedman, A., Goddard, K. A. B., Khoury, M. J., & Ramsey, S. D. (2012). Stakeholder assessment of the evidence for cancer genomic tests: Insights from three case studies. Genetics in Medicine, 14(7), 656-662. https://doi.org/10.1038/gim.2012.3